Coverage from the ASCO20 Virtual Scientific Program
Focus on Metastatic Colorectal Cancer
Positive Results for Off-the-Shelf Metastatic CRC Immunotherapy
Researchers presented positive final data from a phase I/II study of PolyPEPI1018, an off-the-shelf multi-peptide treatment, in microsatellite stable metastatic colorectal cancer (MSS mCRC) patients during an online poster presentation at the 2020 ASCO Annual Meeting (Abstract 4048).
Pembrolizumab Effective, Produces Durable Responses Over 3 Years in MSI-H mCRC
Long-term treatment with pembrolizumab was associated with durable responses and significant antitumor immunity over 3 years in patients with advanced colorectal cancer (CRC) and metastatic microsatellite instability-high (MSI-H) tumors who were enrolled in the phase II KEYNOTE-164 study. This is according study author Luis A. Diaz, MD, of the Memorial Sloan Kettering Cancer Center, who presented the findings from the trial at the ASCO 2020 Annual Meeting (Abstract 4032).
For the first time ever, ASCO’s Annual Meeting is going Virtual. Despite the change in format, the meeting will still be the year’s biggest platform for sharing the latest research in hematology/oncology. Hematologist/oncologists around the world will be able to discover and discuss pioneering research, therapies, and state-of-the-art treatments that are transforming cancer care.
Nivolumab + Ipilimumab Produces Durable Responses in Metastatic Colorectal Cancer
First-line nivolumab plus low-dose ipilimumab over a 2-year period was associated with durable clinical benefit and deepening responses and featured a good tolerability profile in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC), according to long-term follow-up data from the phase II CheckMate-142 trial, which were presented at the ASCO 2020 Annual Meeting (Abstract 4040).
Uncovering Sex Differences in Colorectal Cancer Treatment
A study presented at the 2020 ASCO Annual Meeting confirmed that palliative chemotherapy for metastatic colorectal cancer (mCRC) has a higher toxicity in women, but its efficacy is not better (Abstract 4029). The finding has implications for the future of precision medicine and continues the discussion around sex as a modulator of cancer biology and treatment outcomes.
Pembrolizumab as Firstline Therapy for Advanced Colorectal Cancer With Mismatch Repair Deficiency
Frontline therapy with the immune checkpoint inhibitor pembrolizumab should be considered the new standard of care for patients with microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (CRC), according to the results of a new study.